12. ЛИТЕРАТУРА

Поставить закладку

1 . Иммунная тромбоцитопения: клинические проявления и ответ на терапию. Промежуточный анализ данных Российского регистра пациентовспервичнойиммуннойтробоцитопениейиобзорлитературы. И.А.Лисуков, А.А.Масчан, А.В.Шамардина, Т.В.Чагорова, И.Л.Давыдкин, Т.М.Сычева, Т.П.Загоскина, Е.В.Карагина, Г.Н.Салогуб, М.Т.Савинова, Т.В.Шелехова, Л.Г.Ковалева, Т.В.Шнейдер, А.Н.Унжекова, Е.Е.Кузнецова, Ю.В.Шатохин, М.О.Иванова,
Е .Ю.Виноградова, Е.М.Володичева, И.В.Маркова, О.В.Канюкова, К.М.Абдулкадыров, Ю.А.Седлова, С.М.Осюнихина, К.Д.Капланов, Н.В.Цветаева, А.Р.Ахмалеев, О.С.Успенская, А.Д.Кулагин, Н.В.Медведева,А.Г.Румянцев,Б.В.Афанасьев.Онкогематология,2013г., №2,с.61-69.
2 . Ковалева Л.Г., Сафонова Т.И., Пустовая Е.И., Колосова Е.Н., Рядненко А.А. Клинико-статистические данные и оценка различных методов терапии идиопатической тромбоцитопенической пурпуры. Терапевтическийархив,2011;4:60-65.
3 . Рекомендации Российскогосовета экспертовпо диагностикеи лечению больных первичной иммунной тробоцитопенией. А.А.Масчан, А.Г.Румянцев, Л.Г.Ковалева, Б.В.Афанасьев, Т.И.Поспелова, А.Ю.Зарицкий, К.М.Абдулкадыров, В.В.Птушкин, Н.В.Цветаева, И.А.Лисуков, Г.Н.Салогуб, А.К.Голенков, Н.В.Медведева, О.А.Рукавицин,В.Л.Иванова,И.В.Маркова.Онкогематология,2010г.,№ 3,с.36-45.
4 . AledortL.M.,HaywardC.P.,ChenM.G.,NicholJ.L.,BusselJ.Prospective screeningof205patientswithITP,includingdiagnosis,serologicalmarkers andtherelationshipbetweenplateletcounts,endogenousthrombopoietin,and circulatingantithrombopoietinantibodies.AmJHematol2004;76(3):205-13.
5 . Alpdogan O., Budak-Alpdogan T., Ratip S. et.al. Efficasy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenicpurpura.BrJHaematol1998;103(4):1061-3.
6 . AndersenJ.C.,Responseofresistantidiopathicthrombocytopenicpurpurato pulsedhigh-dosedexamethasonetherapy.NEnglJMed.,1994;30(22):1560-4.
7 . Balmer P., Falconer M., McDonald P., et.al. Immune response to meningocococcal serogroup C conjugate vaccine in asplenic individuals. InfectImmun2004;72(1):332-7.
8 . Ben-Yehuda D., Gillis S., Eldor A. Clinical and theraupeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol 1994; 91(1): 1-6.
9 . Boruchov D.M., Gururangan S., Driscoll M.C., Bussel J.B. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood, 2007; 110(10): 3526-31.
10 .Brighton T.A., Evans S., Castaldi P.A., Chesterman C.N., Chong B.H. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood, 1996; 88(1): 194-201.
11 .Bussel J. Intravenous immune serum globulin in immune thrombocytopenic purpura: clinical results and biochemical evaluation. Vox Sang 1985; 49(Suppl 1): 44-50.
12 .Bussel J.B. Autoimmune thrombocytopenic purpura. Hematol Oncol Clin North Am 1990; 4(1): 179-91.
13 .Bussel J.B., Cheng G., Saleh M.N. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357(22):2237-47.
14 .Bussel J.B., Kuter D.J., George J.N. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355(16): 1672-81.
15 .Bussel J.B., Kuter D.J., Pullarkat V. et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113(10):2161-71.
16 .Bussel J.B., Provan D., Shamsi T. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373(9664): 641-8.
17 .Center for Disease Control. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immunoglobulins in persons with altered immunocompetence. MMWR 1993;42 (RR-4):1-18.
18 .Douglas B. Clines and James B. Bussel “How I treat ITP” - Blood 2005, 106: 2244-2251
19 .Clinical Practice Guideline on the Evaluation and Management of Immune Thombocytopenia (ITP), 2011
20 .Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160(11):1630-8.
21 .Davoren A., Bussel J., Curtis B.R., Moghaddam M., Aster R.H., McFarland J.G. Prospctive evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in he diagnosis of autoimmune thrombocytopenia (AITP). Am J Hematol. 2005; 78(3): 193-197.
22 .de Montalembert M., Lenoir G. Antibiotic prevention of pneumococcal infections in asplenic hosts: admission of insufficiency. Ann Hematol 2004;83(1):18-21.
23 .Figueroa M., Gehlsen J., Hammond D. et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993;328(17):1226-9.
24 .Fogarty P. Chronic ITP in adults: epidemiology and clinical presentation. HematolOncolClin N Am: 2009. 23: 1213-1221.
25 .George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88: 3-46.
26 .Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120(4): 574-96.
27 .Houwerzijl E.J., Blom N.R., van der Want J.J. et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103(2):500-6.
28 .Jenkins J.M., Williams D., Deng Y. et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109(11):4739-41.
29 .Johansson E., Engervall P., Landgren O. et al. Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura. Eur J Haematol 2006;77(1):61-6.
30 .Jubelirer S.J., Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost 2002; 8(1): 73-6.
31 .Kaplinsky C., Spirer Z. Post-splenectomy antibiotic prophylaxis-unfinished story: to treat or not to treat? Pediatr Blood Cancer 2006;47(Suppl 5):740-1.
32 .Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995;74(1):521-5.
33 .Keidar A., Sagi B., Szold A. Laparoscopic splenectomy for immune thrombocytopenic purpura in patients with severe refractory thrombocytopenia. Pathophysiol Haemost Thromb 2003;33(2):116-9.
34 .Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623-34.
35 .Kuhne Tomas “Immune Thrombocytopenia (ITP)” Uni-Med Verlag AG 2012.
36 .Kumagai Y., Fujita T., Ozaki M. et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebocontrolled study. J Clin Pharmacol 2007;47(12):1489-97.
37 .Kuter D.J. New thrombopoietic growth factors. Blood 2007;109(11):4607-16.
38 .Kuter D. et al. Evaluation of efficacy and safety of long-term romiplostim treatment for patients with immune thrombocytopenia (ITP) enrolled in an open-label extension study: A patient cohortanalysis. EHA 2010: Abstract №0189.
39 .Kuter D.J., Bussel J.B., Lyons R.M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a doubleblind randomised controlled trial. Lancet 2008; 371(9610):395-403.
40 .D Kuter et.al. Romiplostim or standart of care in patients with ITP - N Engl J Med 2010; 363(20):1889-1899
41 .Liebman H. Other immune thrombocytopenias. Semin Hematol 2007; 44(4Suppl5):24-34.
42 .Liebman H.A., Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Haematol 2007; 14(5): 557-73.
43 .Mak Y.K., Yu P.H., Chan C.H., Chu Y.C. The management of isolated thrombocytopenia in Chinese adults: does bone marrow examination have a role at presentation? Clin Lab Haematol 2000; 22(6): 355-8.
44 .Mazzuconi M.G., Fazi P., Bemasconi S. et.al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GINEMA experience. Blood 2007; 109(4): 1401-7.
45 .McMillan R., Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004;104(4):956-60.
46 .McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 2001;344(18):1402-3.
47 .McMillan R., Bussel J.B., George J.N., Lalla D., Nichol J.L. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008;83(2):150-4.
48 .McMillan R., Wang L., Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003; 1(3): 485-91.
49 .Miller E., Waight P., Farrington C.P. et.al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84(3): 227-229.
50 .Neunert C., Wendy Lim, Mark Crowther, Alan Cohen, Lawrence Solberg, Jr and Mark A. Crowther. The American Society of Hematology 2011 evidencebased practice guideline for immune thrombocytopenia. Blood 2011, 117: 4190-4207.
51 .Newland A.C., Treleaven J.G., Minchinton R.M., Waters H. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 1(8316): 84-7.
52 .Newland A., Caulier M.T., Kappers-Klunne M. et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesisstimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006;135(4):547-553.
53 .Newland A., Provan D., Myint S. Preventing severe infection after splenectomy. BMJ 2005;331(7514):417-8.
54 .Pizzuto J., Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984; 64(6): 1179-83.
55 .Portielje J.E., Westendorp R.G., Kluin-Nelemans H.C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97(9):2549-54.
56 .Provan D., Roberto Stasi, Adrian C. Newlnd, Victor S. Blanchette, Paula Bolton-Maggs, James B. Bussel, Beng H. Chong, Douglas B. Clines, Terry Gernsheimer, etc. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115: 168186.
57 .Psaila B., Bussel J.B. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008;143(1):16-26.
58 .Rodeghiero F., Roberto Stasi, Terry Gernsheimer, Marc Michel, Drew Provan, Donald M.Arnold, James B. Bussel, Douglas B. Clines, etc. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from international working group. Blood 2009, 113: 2386-2393.
59 .Schiavotto C., Ruggeri M., Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of literature. Haematologica 1993; 78(6 Suppl 2): 35-40.
60 .Schwartz J., Leber M.D., Gillis S. et al. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003;72(2):94-8.
61 .Stasi R., Brunetti M., Pagano A., et.al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000; 26(6): 582-6.
62 .Stasi R., Sarpatwari A., Segal J.B. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood, 2009; 113(6): 1231-40.
63 .Stasi R., Stipa E., Masi M., et.al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98(5): 436-42.
64 .Stasi R., Stipa E., Masi M., et.al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84(12): 4203-8.
65 .Stockelberg D., Hou M., Jacobsson S., Kutti J., Wadenvik H. Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP): a comparative study using flow cytometry, a whole platelet ELISA, and antigen capture ELISA. Eur J Haematol. 1996; 56(1-2): 72-77.
66 .Vianelli N., Galli M., de Vivo A. et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005;90(1):72-7.
67 .Wasser J. Et.al. - Use of rituximab in a study comparing the romiplostim with standard of care in patients with ITP - Blood 2011; 118(21):3282.
68 .Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective, 11-year analysis of obstetrical patients with idiopathic thrombocytopenic purpura. Blood. 2003;102:4306-4311.
69 .Wong G.C., Lee L.H. A study of idiopathic thrombocytopenic purpura (ITP) patients over a ten-year period. Ann Acad Med Singapore 1998; 27(6): 789793.
70 .Yang R., Han Z.C. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update. Int J Hematol 2000; 71(1): 18-24.